Condition: Breast Cancer Female · Sponsor: Institut Paoli-Calmettes
The present project aims at identifying robust candidates for drug resistance in BC patients eligible for NAC. Its originality lies upon the combination of three different and complementary prospective approaches: from the molecular analyses of biopsies sampled before and after NAC, from in vitro BC Patient-Derived Organoids (PDO) mimicking patient's response to NAC, and from Circulating Tumor Cells (CTCs) isolated before/during/after NAC.
This description comes directly from the study's public registry record.
j PAKRADOUNI, PharmD,PhD · 0491223778 · drci.up@ipc.unicancer.fr
Laurie-Anne GOUTY, PhD · 33491223778 · drci.up@ipc.unicancer.fr
Always discuss trial participation with your own doctor first.
| Institut Paoli-Calmettes | Marseille, Marseille, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04504747